Preclinical and Clinical Experience with Liposome-Encapsulated Mitoxantrone

References

• Von Hoff D.D., Pollard E., Kuhn J., Murray E., Coltman C.A.J. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (((2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res. 1980; 40: 1516
   PubMed Web of Science ®Google Scholar
• White R.J., Durr F.E. Development of mitoxantrone. Invest.New Drugs 1985; 3: 85
   PubMed Web of Science ®Google Scholar
• Hagenberg L., Loynds P., Nagel G.A. [Mitoxantrone HCl (1,4-dihydroxy-4, 8-bis[[2-(hydroxyethyl)-amino-ethyl)]amino 9,10-anthracenedione dihydrochloride (NSC 301739) - a new cytostatic]. Onkologie. 1980; 3: 322
   PubMedGoogle Scholar
• Alberts D.S., Peng Y.M., Bowden G.T., Dalton W.S., Mackel C. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest.New Drugs 1985; 3: 101
   PubMed Web of Science ®Google Scholar
• Birchall L.A., Bailey N.P., Blackledge G.R. An overview of mitozantrone. Br.J.Clin.Pract. 1991; 45: 208
   PubMedGoogle Scholar
• Faulds D., Balfour J.A., Chrisp P., Langtry H.D. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 41: 400
   PubMed Web of Science ®Google Scholar
• Posner L.E., Dukart G., Goldberg J., Bernstein T., Cartwright K. Mitoxantrone: an overview of safety and toxicity. Invest.New Drugs 1985; 3: 123
   PubMed Web of Science ®Google Scholar
• Shenkenberg T.D., Von Hoff D.D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann.Intern.Med. 1986; 105: 67
   PubMed Web of Science ®Google Scholar
• Smyth J.F., Macpherson J.S., Warrington P.S., Leonard R.C., Wolf C.R. The clinical pharmacology of mitozantrone. Cancer Chemother.Pharmacol. 1986; 17: 149
   PubMed Web of Science ®Google Scholar
• Allegra J.C., Woodcock T., Woolf S., Henderson I.C., Bryan S., Reisman A., Dukart G. A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. Invest.New Drugs 1985; 3: 153
   PubMed Web of Science ®Google Scholar
• Astone A., Cassano A., Fontana T., Noviello M.R., Pozzo C., Barone C. Salvage chemotherapy with mitoxantrone and mitomycin with or without methotrexate in advanced breast cancer. Anticancer Drugs 1992; 3: 471
   PubMed Web of Science ®Google Scholar
• Bontenbal M., Planting A.S., Rodenburg C.J., Dees A., Verweij J., Bartels C.C., Alexieva Figusch J., van Putten W.L., Klijn J.G. Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer. Breast Cancer Res. Treat. 1992; 21: 133
   PubMed Web of Science ®Google Scholar
• Broun E.R., Sledge G.W., Einhorn L.H., Tricot G.J. High-dose carboplatin and mitoxantrone with autologous bone marrow support in the treatment of advanced breast cancer. Am.J.Clin.Oncol. 1993; 16: 9
   PubMed Web of Science ®Google Scholar
• Leiby J.M., Unverfurth D.V., Neidhart J.A. High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial. Cancer Treat.Rep. 1986; 70: 899
   PubMedGoogle Scholar
• Robertson J.F., Williams M.R., Todd J.H., Blarney R.W. Mitoxantrone - a useful palliative therapy in advanced breast cancer. Am.J.Clin.Oncol. 1989; 12: 393
   PubMed Web of Science ®Google Scholar
• Shpall E.J., Jones R.B., Holland J.F., Bhardwaj S., Paciucci P.A., Wilfinger C.L., Strashun A. Intensive single-agent mitoxantrone for metastatic breast cancer. J.Natl.Cancer Inst. 1988; 80: 204
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W.W., Clavel M., Rodenhuis S., Guastalla J.P., Franklin H.R., Koier J.J., Vlasveld T., Dalesio O., van Tinteren H., Pinedo H.M. Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer. Pathol.Biol.Paris. 1992; 39: 962
   PubMedGoogle Scholar
• Arlin Z.A., Silver R., Cassileth P., Armentrout S., Gams R., Daghestani A., Coleman M., Schoch I., Dukart G. Phase I-II trial of mitoxantrone in acute leukemia. Cancer Treat.Rep. 1985; 69: 61
   PubMedGoogle Scholar
• Amadori S., Arcese W., Isacchi G., Meloni G., Petti M.C., Monarca B., Testi A.M., Mandelli F. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J.Clin.Oncol. 1991; 9: 1210
   PubMed Web of Science ®Google Scholar
• Archimbaud E., Leblond V., Michallet M., Cordonnier C., Fenaux P., Travade P., Dreyfus F., Jaubert J., Devaux Y., Fiere D. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991; 77: 1894
   PubMed Web of Science ®Google Scholar
• Bezwoda W.R., Bernasconi C., Hutchinson R.M., Winfield D.A., de Bock R., Mandelli F. Mitoxantrone for refractory and relapsed acute leukemia. Cancer 1990; 66: 418
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Aul C., Maschmeyer G., Schonrock Nabulsi R., Ludwig W.D., Bartholomaus A., Bettelheim P., Becker K., Balleisen L., Lathan B. High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison. Semin.Hematol. 1991; 28: 35
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Kreutzmann H., Straif K., Ludwig W.D., Donhuijsen Ant R., Lengfelder E., Arlin Z., Buchner T. High-dose cytosine-arabinoside and mitoxantrone in refractory acute myeloid leukemia: a clinical phase I/II-study. Onkologie. 1986; 9: 144
   PubMedGoogle Scholar
• Wahlin A., Hornsten P., Hedenus M., Malm C. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemother.Pharmacol. 1991; 28: 480
   PubMed Web of Science ®Google Scholar
• Bajetta E., Buzzoni R., Valagussa P., Bonadonna G. Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas. Am. J.Clin.Oncol. 1988; 11: 100
   PubMed Web of Science ®Google Scholar
• Ho A.D., Del Valle F., Engelhard M., Hiddemann W., Ruckle H., Schlimok G., Haas R., Thiel E., Andreesen R., Fiedler W. Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study. Cancer 1990; 66: 423
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Schmitz N., Pfreundschuh M., Pfluger K.H., Ollech Chwoyka J., Tirier C., Maschmeyer G., Kirchner H., Wagner T., Koch P. Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group. Cancer 1990; 66: 838
   PubMed Web of Science ®Google Scholar
• Lim S.H., Baglin T.P., Flavell D.J., Flavell S.U., Wimperis J.Z., Marcus R.E. High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease. Eur.J.Haematol. 1992; 48: 110
   PubMed Web of Science ®Google Scholar
• Gams R.A., Bryan S., Dukart G., Weiss A., Case D., Jones S., Stein R. Mitoxantrone in malignant lymphoma. Invest.New Drugs 1985; 3: 219
   PubMed Web of Science ®Google Scholar
• Hansen S.W., Nissen N.I., Hansen M.M., Hou Jensen K., Pedersen Bjergaard J. High activity of mitoxantrone in previously untreated low-grade lymphomas. Cancer Chemother.Pharmacol. 1988; 22: 77
   PubMed Web of Science ®Google Scholar
• Alberts D.S., Balcerzak S.P., Bonnet J.D., Stephens R.L. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study. Cancer Treat.Rep. 1985; 69: 1321
   PubMedGoogle Scholar
• Hiddemann W., Buchner T., Heil G., Schumacher K., Diedrich H., Maschmeyer G., Ho A.D., Planker M., Gerith Stolzenburg S., Donhuijsen Ant R. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 1990; 4: 637
   PubMed Web of Science ®Google Scholar
• Arlin Z.A., Feldman E.J., Finger L.R., Ahmed T., Mittelman A., Cook P., Puccio C., Baskind P., Arnold P., Razis E.D. Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 1991; 5: 712
   PubMed Web of Science ®Google Scholar
• Arlin Z., Case D.C.J., Moore J., Wiernik P., Feldman E., Saletan S., Desai P., Sia L., Cartwright K. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 1990; 4: 177
   PubMed Web of Science ®Google Scholar
• Behar C., Bertrand Y., Rubie H., Vilmer E., Babin A., Brock P., Boutard P., Solbu G., Suciu S., Robert A. Mitoxantrone and high dose Ara-C for the treatment of ANLL in childhood: a pilot study of the EORTC CLCG (EORTC 58 872). Leukemia 6, Suppl 1992; 2: 63
   Google Scholar
• Dutcher J.P., Eudey L., Wiernik P.H., Paietta E., Bennett J.M., Arlin Z., Kellermeyer R., Rowe J., O'Connell M., Oken M. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia 1992; 6: 770
   PubMed Web of Science ®Google Scholar
• Hansen M.M., Hansen S.W., Pedersen Bjergaard J., Nissen N.I. Mitoxantrone in the treatment of chronic lymphocytic leukemia. Leuk.Lymphoma. 1992; 7: 305
   PubMed Web of Science ®Google Scholar
• Arseneau J.C., Schoenfeld D.A., Borden E.C. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma. Invest.New Drugs 1986; 4: 53
   PubMed Web of Science ®Google Scholar
• Sridhar K.S., Hussein A.M., Benedetto P., Waldman S.M., Feun L.G., Savaraj N., Richman S.P., Ardalan B., Desai P. Phase II trial of mitoxantrone in head and neck carcinoma. AmJ.Clin.Oncol. 1991; 14: 298
   PubMed Web of Science ®Google Scholar
• Bull F.E., Von Hoff D.D., Balcerzak S.P., Stephens R.L., Panettiere F.J. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study. Cancer Treat.Rep. 1985; 69: 231
   PubMedGoogle Scholar
• Gams R.A., Nelson O., Birch R. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial. Cancer Treat.Rep. 1986; 70: 921
   PubMedGoogle Scholar
• Taylor S.A., Fleming T., Von Hoff D.D., McCracken J.D., Bukowski R.M., Talley R.W., Natale R.B., Guy J.T., Samlowski W.E., Costanzi J.H. Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group study. Invest.New Drugs 1990; 8: 77
   PubMed Web of Science ®Google Scholar
• Coleman R., Clarke J., Gore M., Wiltshaw E., Slevin M., Harper P. A phase II study of mitozantrone in advanced carcinoma of the ovary. Cancer Chemother.Pharmacol. 1989; 24: 200
   PubMed Web of Science ®Google Scholar
• Hording U., Rose C., Jakobsen K., Dirksen H. Mitoxantrone in advanced cervical carcinoma: a phase II study in patients not previously treated with chemotherapy. Cancer Treat.Rep. 1986; 70: 1239
   PubMedGoogle Scholar
• Osborne C.K., Blumenstein B.A, Crawford E.D., Weiss G.R., Bukowski R.M., Larrimer N.R. Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur.J.Cancer 1992; 28: 477
   PubMedGoogle Scholar
• Colleoni M., Nole F., Di Bartolomeo M., de Braud F., Bajetta E. Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. Oncology 1992; 49: 139
   PubMed Web of Science ®Google Scholar
• Dunk A.A., Scott S.C., Johnson P.J., Melia W., Lok A.S., Murray Lyon I., Williams R., Thomas H.C. Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study. J.Hepatol. 1985; 1: 395
   PubMed Web of Science ®Google Scholar
• Lai K.H., Tsai Y.T., Lee S.D., Ng W.W., Teng H.C., Tarn T.N., Lo G.H., Lin H.C., Lin H.J., Wu J.C. Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemother.Pharmacol. 1989; 23: 54
   PubMed Web of Science ®Google Scholar
• Yoshida T., Okazaki N., Yoshino M., Ohkura H., Miyamoto K., Shimada Y. Phase II trial of mitoxantrone in patients with hepatocellular carcinoma. Eur.J.Cancer Clin.Oncol. 1988; 24: 1897
   PubMedGoogle Scholar
• Davis R.B., Van Echo D.A., Leone L.A., Henderson E.S. Phase II trial of mitoxantrone in advanced primary liver cancer: a Cancer and Leukemia Group B Study. Cancer Treat.Rep. 1986; 70: 1125
   PubMedGoogle Scholar
• Falkson G., Coetzer B.J. Phase II studies of mitoxantrone in patients with primary liver cancer. Invest.New Drugs 1985; 3: 187
   PubMed Web of Science ®Google Scholar
• O'Reilly S.M., Coleman R.E., Rubens R.D. Phase II study of mitoxantrone for liver metastases from breast cancer. Cancer Chemother.Pharmacol. 1989; 25: 73
   PubMed Web of Science ®Google Scholar
• Sharifi R., Lee M., Clayton M., Lamb D., Siami P., Strub M., Albert D., Sarosdy M. Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer. Anticancer Drugs 1991; 2: 153
   PubMed Web of Science ®Google Scholar
• Stewart D.J., Green R., Futter N., Walsh W., McKay D., Verma S., Maroun J.A., Redmond D. Phase I and pharmacology study of intravesical mitoxantrone for recurrent superficial bladder tumors. J.Urol. 1990; 143: 714
   PubMed Web of Science ®Google Scholar
• Blochl Daum B., Eichler H.G., Rainer H., Jakesz R., Salzer H., Steger G., Schuller J., Gunther E., Proksch B., Ehninger G. Escalating dose regimen of intraperitoneal mitoxantrone: phase I study - clinical and pharmacokinetic evaluation. Eur.J.Cancer Clin.Oncol. 1988; 24: 1133
   PubMedGoogle Scholar
• Dufour P., Maloisel F., Bergerat J.P., Barats J.C., Dellenbach P., Renaud R., Ritter P., Herbrecht R., Wendling C., Audhuy B. Intraperitoneal mitoxantrone as consolidation treatment for stage III ovarian carcinoma: a pilot study. Bull.Cancer Paris. 1991; 78: 273
   PubMed Web of Science ®Google Scholar
• Groth G., Gatzemeier U., Haussingen K., Heckmayr M., Magnussen H., Neuhauss R., Pavel J.V. Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann.Oncol. 1991; 2: 213
   PubMed Web of Science ®Google Scholar
• Markman M., Hakes T., Reichman B., Lewis J.L.J., Rubin S., Jones W., Almadrones L., Hoskins W. Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer. J.Clin.Oncol. 1991; 9: 978
   PubMed Web of Science ®Google Scholar
• Shepherd F.A., Evans W.K., Blackstein M.E., Fine S., Heathcote J., Langer B., Taylor B., Habal F., Kutas G., Pritchard K.I. Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. J.Clin.Oncol. 1987; 5: 635
   PubMed Web of Science ®Google Scholar
• Torsten U., Opri F., Weitzel H. Local therapy of malignant pleural effusion with mitoxantrone. Anticancer Drugs 1992; 3: 17
   PubMed Web of Science ®Google Scholar
• van Breukelen F.J., Mattson K., Giaccone G., van Zandwijk N., Planteydt H.T., Kirkpatrick A., Dalesio O. Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur.J.Cancer 1991; 27: 1627
   PubMed Web of Science ®Google Scholar
• Henderson I.C., Allegra J.C., Woodcock T., Wolff S., Bryan S., Cartwright K., Dukart G., Henry D. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J.Clin.Oncol. 1989; 7: 560
   PubMed Web of Science ®Google Scholar
• Stewart D.J., Perrault D.J., Maroun J.A., Lefebvre B.M. Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. Am. J.Clin. Oncol. 1987; 10: 335
   PubMed Web of Science ®Google Scholar
• Cowan J.D., Neidhart J., McClure S., Coltman C.A.J., Gumbart C., Martino S., Hutchins L.F., Stephens R.L., Vaughan C.B., Osborne C.K. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J.Natl.Cancer Inst. 1991; 83: 1077
   PubMedGoogle Scholar
• Greidanus J., de Vries E.G., Mulder N.H., Sleijfer D.T., Uges D.R., Oosterhuis B., Willemse P.H. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J.Clin.Oncol. 1989; 7: 790
   PubMed Web of Science ®Google Scholar
• Kreisle W.H., Alberts D.S., List A.F., McCloskey T., Plezia P., Peng Y.M., George M. A phase I trial of 14-day continuous intravenous infusion mitoxantrone. Anticancer Drugs 1991; 2: 251
   PubMed Web of Science ®Google Scholar
• Dukart G., Iatropoulos M.J., Yacobi A. Comment on mitoxantrone. Drug Intell.Clin.Pharm. 1985; 19: 216
   PubMedGoogle Scholar
• Fisher G.R., Patterson L.H. DNA strand breakage by peroxidase-activated mitoxantrone. J.Pharm.Pharmacol. 1991; 43: 65
   PubMed Web of Science ®Google Scholar
• Heinemann V., Murray D., Walters R., Meyn R.E., Plunkett W. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother.Pharmacol. 1988; 22: 205
   PubMed Web of Science ®Google Scholar
• Hubalek F. Detection of single-strand breaks in DNA induced by mitoxantrone in experimental tumors after in vivo treatment. Neoplasma. 1991; 38: 101
   PubMed Web of Science ®Google Scholar
• Novak R.F., Kharasch E.D. Mitoxantrone: propensity for free radical formation and lipid peroxidation—implications for cardiotoxicity. Invest.New Drugs 1985; 3: 95
   PubMed Web of Science ®Google Scholar
• Smith P.J., Morgan S.A., Fox M.E., Watson J.V. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem.Pharmacol. 1990; 40: 2069
   PubMed Web of Science ®Google Scholar
• Jensen P.B., Vindelov L., Roed H., Demant E.J., Sehested M., Skovsgaard T., Hansen H.H. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Br.J Cancer 1989; 60: 838
   PubMed Web of Science ®Google Scholar
• Wallace R.E., Lindh D., Durr F.E. Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro. Cancer Invest. 1987; 5: 417
   PubMed Web of Science ®Google Scholar
• Ehninger G., Schuler U., Proksch B., Zeller K.P., Blanz J. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin.Pharmacokinet. 1990; 18: 365
   PubMed Web of Science ®Google Scholar
• Blanz J., Mewes K., Ehninger G., Proksch B., Greger B., Waidelich D., Zeller K.P. Isolation and structure elucidation of urinary metabolites of mitoxantrone. Cancer Res. 1991; 51: 3427
   PubMed Web of Science ®Google Scholar
• Balazsovits J.A., Mayer L.D., Bally M.B., Cullis P.R., McDonell M., Ginsberg R.S., Falk R.E. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother.Pharmacol. 1989; 23: 81
   PubMed Web of Science ®Google Scholar
• Gabizon A., Shiota R., Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst. 1989; 81: 1484
   PubMed Web of Science ®Google Scholar
• Gabizon A., Amselem S., Goren D., Cohen R., Druckmann S., Fromer I., Chisin R., Peretz T., Sulkes A., Barenholz Y. Preclinical and clinical experience with a doxorubicin-liposome preparation. J.Liposome Res. 1990; 1: 491
   Google Scholar
• Gabizon A., Peretz T., Sulkes A., Amselem S., Ben Yosef R., Ben Baruch N., Catane R., Biran S., Barenholz Y. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur. J. Cancer Clin. Oncol. 1989; 25: 1795
   PubMedGoogle Scholar
• Gabizon A., Chisin R., Amselem S., Druckmann S., Cohen R., Goren D., Fromer I., Peretz T., Sulkes A., Barenholz Y. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br.J. Cancer 1991; 64: 1125
   PubMed Web of Science ®Google Scholar
• Gabizon A.A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992; 52: 891
   PubMed Web of Science ®Google Scholar
• Rahman A., Fumagalli A., Barbieri B., Schein P.S., Casazza A.M. Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Chemother.Pharmacol. 1986; 16: 22
   PubMed Web of Science ®Google Scholar
• Forssen E.A., Coulter D.M., Proffitt R.T. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992; 52: 3255
   PubMed Web of Science ®Google Scholar
• Mayhew E.G., Lasic D., Babbar S., Martin F.J. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int.J.Cancer 1992; 51: 302
   PubMed Web of Science ®Google Scholar
• Schwendener R.A., Fiebig H.H., Berger M.R., Berger D.P. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Cancer Chemother.Pharmacol. 1991; 27: 429
   PubMed Web of Science ®Google Scholar
• Pestalozzi B., Schwendener R., Sauter C. Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann.Oncol. 1992; 3: 445
   PubMed Web of Science ®Google Scholar
• Madden T.D., Harrigan P.R., Tai L.C., Bally M.B., Mayer L.D., Redelmeier T.E., Loughrey H.C., Tilcock C.P., Reinish L.W., Cullis P.R. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem.Phys.Lipids 1990; 53: 37
   PubMed Web of Science ®Google Scholar
• Law S.L., Chang P., Lin C.H. Characteristics of mitoxantrone loading on liposomes. Biochim.Biophys.Acta 1991; 70: 1
   Google Scholar
• Beck P., Kreuter J., Reszka R., Fichtner I. Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drag mitoxantrone in murine tumor models. J.Microencaps. 1993; 10: 101
   PubMed Web of Science ®Google Scholar
• Rubas W., Supersaxo A., Weder H.G., Hartmann H.R., Hengartner H., Schott H., Schwendener R.A. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int.J. Cancer 1986; 37: 149
   Web of Science ®Google Scholar
• Schwendener R.A., Schott H. Treatment of L1210 murine leukemia with liposome - incorporated N4-hexadecyl-1-β-D-arabinofuranosylcytosine. Int.J. Cancer 1992; 51: 466
   PubMed Web of Science ®Google Scholar
• Schwendener R.A. The preparation of large volumes of homogenous, sterile liposomes containing various lipophilic cytostatic drugs by the use of a capillary dialyzer. Cancer Drug Deliv. 1986; 3: 123
   PubMedGoogle Scholar
• Schwendener R.A. The preparation of large volumes of sterile liposomes for clinical applications. Liposome Technology Vol. I, 2nd Edition, G. Gregoriadis. CRC Press, Cleveland 1992; 487
   Google Scholar
• Allen T.M., Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta 1991; 1068: 133
   PubMed Web of Science ®Google Scholar
• Sommerman E.F., Pritchard P.H., Cullis P.R. 125-labeled inulin: a convenient marker for deposition of liposomal contents in vivo. Biochem.Biophys.Res.Commun. 1984; 122: 319
   PubMed Web of Science ®Google Scholar
• Allen T.M. Stealth-liposomes: Avoiding reticuloendothelial uptake. Liposomes in the therapy of infectious diseases and cancer, G. Lopez-Berenstein, I.J. Fidler. Alan R. Liss, New York 1989; 405
   Google Scholar
• Hänseler E., Rentsch K., Horber D.H., Schwendener R.A., Sauter Chr. Pharmacokinetics of free and liposomal formulations of mitoxantrone in mice and patients with advanced breast cancer. Proc.AACR 1993; 34: 346
   Google Scholar
• Eichler H.G., Mader R., Blochl Daum B., Steger G., Rainer H. Poly(I).poly(C), a potential drug carrier for the antitumor agent mitoxantrone: in vitro drug binding study. Cancer Chemother.Pharmacol. 1987; 20: 81
   PubMed Web of Science ®Google Scholar
• Bally M.B., Nayar R., Masin D., Hope M.J., Cullis P.R., Mayer L.D. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim.Biophys.Acta 1990; 1023: 133
   PubMed Web of Science ®Google Scholar
• Gabizon A., Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim.Biophys.Acta 1992; 1103: 94
   PubMed Web of Science ®Google Scholar